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Abstract: Blood banks use pathogen inactivation (PI) technologies to increase the safety of platelet
concentrates (PCs). The characteristics of PI-treated PCs slightly differ from those of untreated PCs,
but the underlying reasons are not well understood. One possible cause is the generation of oxidative
stress during the PI process. This is of great interest since reactive oxygen species (ROS) act as
second messengers in platelet functions. Furthermore, there are links between protein oxidation
and phosphorylation, another mechanism that is critical for cell regulation. Current research efforts
focus on understanding the underlying mechanisms and identifying new target proteins. Proteomics
technologies represent powerful tools for investigating signaling pathways involving ROS and
post-translational modifications such as phosphorylation, while quantitative techniques enable the
comparison of the platelet resting state versus the stimulated state. In particular, redox cysteine is a
key player in platelet activation upon stimulation by different agonists. This review highlights the
experiments that have provided insights into the roles of ROS in platelet function and the implications
for platelet transfusion, and potentially in diseases such as inflammation and platelet hyperactivity.
The review also describes the implication of redox mechanism in platelet storage considerations.
Keywords: activation; aggregation; blood products; phosphorylation; platelet function; platelets;
reactive oxygen species; redox cysteine; transfusion
1. Introduction
Platelets are anucleate cells that are involved not only in hemostasis but also in many inflammatory
processes [1,2]. Platelets are critical in transfusion practices. In the context of transfusion, platelet
concentrates (PCs) are labile blood products used either prophylactically to prevent bleeding or
therapeutically to stop bleeding (Figure 1) [3]. Cold storage of platelets induces modifications in
platelet membranes. Cold storage also results in novel structures that are related to the associations of
specific sugar structures that lead to the elimination of platelet after transfusion within the Kupffer
cells of the liver [4]. Thus, PCs are mainly stored under agitation at room temperature (RT) until use
for a maximum of five or seven days, depending on institutional specifications. Because there is a risk
of bacterial growth during RT storage, as well as the danger of other emerging (undetected) pathogens,
several countries now use pathogen inactivation technologies (PITs) to ensure a safer product [5].
Indeed, since the introduction of PITs adverse transfusion reactions and transfusion-transmitted
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infections have decreased dramatically [6]. Currently, there are two main commercially available PITs:
INTERCEPT™ (Cerus, Concord, MA, USA) and Mirasol® (Terumo BCT, Lakewood, CO, USA). A third
PIT, THERAFLEX UV (Macopharma, Tourcoing, France), is being tested in a clinical phase III study.
PITs exploit the anucleate nature of platelets and irreversibly crosslink or damage genetic material,
thereby inactivating bacteria, viruses, and parasites [6].
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Damage to the epithelial wall of a vein exposes vWF and collagen. Receptors on platelets, such as
glycoprotein Ib-IX (GP-Ib-IX), αIIbβ3, and glycoprotein VI (GPVI), reversibly bind to newly-exposed
proteins (1). This nduces int nal signaling, lead to platelet activation (2). Platelets undergo
degranulation (3) and secrete chemokines, including ADP, serotonin, ions like Ca2+, and other molecules
that recruit additional platelets (4). Once activated platelets are bound on the endothelial wall, they
progressively and definitively stick on the vein, changing their shape (5). Activated platelets form
crosslinks via fibrinog n bridges between αIIbβ3 proteins, forming the thrombus (6).
While PITs have proven their efficacy for reducing pathogens in PCs [7], in vitro assays show
that PI-treat d PCs have altered functionality and accelerated metabolism. Importantly, treated PCs
exhibit a higher platelet pre-activation level and are less reactive to stimuli, thus showing lower
efficacy than untreated PCs [8–10]. In addition, a recent study reported that microparticulation was
significantly increased in treated PCs as they approached their expiration date [11]. At the clinical level,
Kerckhoffs et al. observed that inactivated platelets show decreased clinical effectiveness based on
corrected count increment (CCI) after 1 h [12,13]. The result is an increased need for PCs. Nevertheless,
Corash et al. expressed reservations about the use of PI-treated PCs [14]. The Cazenave [15] and Lozano
groups [16] found no significant differences in the clinical effectiveness of PI-treated versus untreated
PCs. Differences in data collection methods make it difficult to compare studies, so the clinical relevance
of PITs in platelet function remains unclear in terms of CCI and bleeding time [17,18]. To summarize,
there is a general consensus that PITs have a negative impact on the in vitro characteristics of PCs, but
the reasons are not completely known or understood.
Oxidative stress is one possible cause of the functional changes in platelets that are observed
in vitro after PIT treatment [19,20]. Indeed, amotosalen and riboflavin, which are the photosensitizers in
INTERCEPT™ and Mirasol®, respectively, can sensitize oxygen molecules via type I or II mechanisms
following excitation by UV light and thereby generate reactive oxygen species (ROS), like 1O2, O2−·,
H2O2, and OH [21,22]. Furthermore, UV light alone can induce the formation of ROS [23], showing that
UV(B) itself can play an active role in platelet functionality in vitro [24]. As a consequence, over time,
an ROS imbalance could potentially impact platelet function in both reversible and irreversible ways.
Several diseases that involve platelets are accompanied or characterized by increased levels of
ROS in their early stages. For instance, atherosclerosis, which occludes coronary vessels, involves
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platelet adhesion, which is enhanced by redox signaling [25]. Immune thrombocytopenia, which
leads to decreased platelet production and increased platelet clearance, is also related to oxidative
stress [26]. Atherothrombosis is the main risk factor in type I and II diabetes due to hyperactive
platelets, and enhanced intracellular production of ROS is among the markers of these diseases [27].
Nevertheless, for more than 20 years ROS have not only been shown to be deleterious, but also
to actively regulate platelet signaling and activation [28]. The results from recent redox proteomic
approaches, together with classical approaches, highlight the importance of a complex redox cellular
system that can influence the resting platelet state [29]. PITs could interfere with this state due to their
intrinsic nature.
PITs are expected to alter the resting oxidative state of platelets by increasing both oxidation
and redox second messenger signaling, for example in apoptosis [30] and in the platelet
activation/aggregation pathway [31,32]. To clarify this, the redox proteome in platelets must be
better understood. Redox proteomics provide tools that can describe these phenomena and that can
be used to monitor both reversible and irreversible modifications of the protein oxidation state that
play roles in biological structures and cell functionality [33]. Accordingly, redox proteomics can help
define a given cellular state, such as aging, activation, and the pre-apoptotic state, and provide a better
understanding of platelet functionality. Moreover, clinicians lack insights into the in vivo behavior of
treated platelets after transfusion; thus, in the age of precision medicine, a better characterization of
PCs could improve transfusion results.
The aim of this review is to provide a state-of-the-art description of the role of ROS in platelets,
with an emphasis on cysteine, which is a key amino acid in redox signaling. The review describes
how PITs are thought to damage the platelet proteome based on mass spectrometry results. It also
analyzes platelet signaling that involves ROS in order to better understand the impact of reversible
oxidation. Within the context of transfusion, the review gives an overview of the cysteine redox state
and its crosstalk with phosphorylation. Finally, discussions are opened on the actual debate on platelet
processing/storage strategies.
2. Alterations and Oxidation of Platelet Proteins
Platelet storage lesions affect cell metabolism, activation and morphology [34–36]. Such lesions
have a non-negligible impact on proteins [37]. Indeed, the use of a combination of multiple proteomic
strategies has revealed a network of proteins involved in platelet activation, cytoskeletal reorganization,
vesicle trafficking, and apoptosis, all of which undergo storage-related changes [37]. To limit
storage-induced stress on platelets, efforts are being made to continuously optimize storage conditions,
e.g., by making changes in the composition of plastic bags and additive solutions as well as by
changing the temperature and agitation conditions. PITs have also been found to exacerbate platelet
storage lesions [37]. Even though platelets are enucleated cells, the platelets remain capable of
synthesizing some proteins [36,38–40]. Indeed, much attention has been focused on the platelet
proteome, which involves more than 4000 proteins to date [41], in order to better define the impact of
PITs on platelet function.
Marrocco et al. used a two dimensional-gel electrophoresis (2D-GE) approach to analyze
changes in platelet proteins after riboflavin/UVB treatment. They found significant changes in
the expression of some relevant proteins, including plekstrin, β-actin, ATP synthase, and the
nuclear chloride channel [42]. Our laboratory used a similar approach and found significant
changes in the expression of two proteins, DJ-1 and glutaredoxin-5, after platelets were subjected to
INTERCEPT™-induced oxidative stress [43]. In addition, Hechler et al. identified three distinct protein
pattern variations (involving plekstrin, integrin-linked protein kinase, and the cytoplasmic protein
NCK2) in INTERCEPT™-treated platelets, also by using 2D-GE [44]. Thiele et al. used a gel-free
approach in which liquid chromatography was coupled to tandem mass spectrometry to analyze
buffy coat-derived PCs. They identified changes in a number of proteins after PI treatment. The most
important and irreversible alterations, observed on days 1 and 5, were alterations in the expression
levels of the PEAR-1, CXCR4, and CLIC4 proteins [45].
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These changes in protein expression can probably be attributed, at least in part, to protein
oxidation processes such as carbonylation. Supporting this notion, Johnson et al. found higher
levels of carbonylation in Mirasol®-treated PCs compared to untreated buffy coat-derived PCs [20].
Carbonyl insertion into proteins occurs mainly by three mechanisms: amino acid backbone scission,
amino acid side chain cleavage, and side chain ketone or aldehyde formation by metal catalysis [46].
Diverse amino acid side chains can undergo oxidation, with lysine, arginine, proline, threonine, and
tryptophan among the most sensitive amino acids [47–49]. Oxygen insertion can drive an important
electronic change and affect the amino acid structure. In addition, singlet oxygen can drive inter-amino
acid reactions that induce the formation of covalent bridges and influence the tertiary structure of
proteins [50].
Carbonylation constitutes an intracellular biomarker of oxidative stress that is often associated
with aging and diseases. It is one of the most common types of protein damage, notably because it
is an irreversible and stable modification that is usually not affected by sample preparation. During
aging, antioxidant cell defenses decrease [51], allowing ROS to interact with DNA, RNA, lipids, and
proteins. In the same way, diseases accompanied by oxidative stress raise the carbonylation level in
the platelet proteome [52]. In general, carbonylated proteins are either repaired by specific enzymes or
processed by the proteolysis machinery. These oxidation reactions can induce partial protein unfolding,
thereby exposing hydrophobic regions and leading to the loss of the protein’s primary function and to
aggregation [20,53]. However, while protein carbonylation is generally considered to be deleterious
and associated with diseases [47], it might well be one of the final steps of the oxidation chain caused
by ROS in platelet activation that participates in redox signaling [54].
Aging and disease might not be the only causes of protein carbonylation in cells. Upon platelet
activation, the platelet proteome undergoes a profound transformation, and the level of protein
carbonylation increases [55]. For instance, thrombin and arachidonic acid stimulation enhance the
carbonylation of platelet proteins [56]. This suggests the involvement of ROS in platelet activation,
leading to carbonylation. Although a few proteins show changes after PI treatment [45], the findings
are difficult to interpret; the findings may partially explain the changes in platelet functionality that are
observed in in vitro tests. In addition, the global impact of carbonylation on the proteome is relatively
low. It is reasonable to hypothesize that subtle changes might occur during PIT treatment or even
during platelet activation in vivo, such as regulation of the redox state.
3. The Role of ROS in Platelet Function
3.1. Platelet Activation Pathways Stimulate ROS Production
There are a few agonist-induced activation pathways that produce ROS, including the collagen,
thrombin, and arachidonic acid activation pathways. The 2′,7′-dichlorodihydrofluorescein diacetate
(H2DCFDA) assay is most often used to measure the ROS level inside cells. After cytosolic hydrolysis,
H2DCFDA can be oxidized into 2′,7′-dichlorofluorescein (DCF), which fluoresces at 520 nm. H2DCFDA
is currently used in flow cytometry analyses for direct and reliable relative quantification of intracellular
ROS. After cytosolic hydrolysis, DCFH can be oxidized into DCF, which fluoresces at 520 nm.
H2DCFDA is currently used in flow cytometry analyses for direct and reliable relative quantification
of intracellular ROS. H2DCFDA is currently used in flow cytometry, allowing direct and reliable
relative quantification of intracellular ROS. One of the main advantages of this technique is that it
allows the rapid detection of ROS, so that short-lived oxidative imbalance can be measured. Using
an H2DCFDA-based assay, Bakdash and Williams found compartmentalization of ROS production
that depended on the stimulated receptor [57]. Stimulation of platelets with convulxin, an agonist
peptide targeting the collagen glycoprotein VI (GPVI) receptor, induces intraplatelet ROS production,
while thrombin, a GPIbα and PARs agonist, induces mainly extracellular ROS formation. Indeed,
upon thrombin activation, Bakdash and William found significantly decreased P-selectin exposure
and αIIbβ3 activation using a combination of the extracellular antioxidants superoxide dismutase
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(SOD) and catalase [57]. Carrim et al. showed that a concerted mechanism involving GPIbα and PAR-4
receptors, the latter of which has a low affinity for thrombin, is involved in generating thrombin-derived
ROS [58]. Indeed, specific cleavage of the thrombin-binding site on GPIbα by the Nk protease at
Tyr276–Asp277 abolishes ROS generation under thrombin stimulation. In addition, in the presence of
the Nk protease, stimulation with PAR-4 agonists such as PAR4-AP and AYPGKF-NH2 substantially
decreases the platelet aggregation percentage [58]. Upon collagen stimulation, ROS generation is
significantly decreased by inhibiting focal adhesion tyrosine kinase in the GPIbα–PAR4 downstream
cascade [59], while the main receptor, PAR-1, which has a high affinity for thrombin, seems to
activate platelets via ROS-independent pathways. Recently, cyclophilin A (CyPA), a bidirectional
regulator of the αIIbβ3 receptor, was identified as a crucial component in the generation of ROS under
thrombin stimulation [60]. CyPA interacts with the p47phox subunit to modulate the assembly of the
cytoplasmic membrane NAD(P)H complex, which generates ROS [61]. Furthermore, flow cytometry
shows that thrombin-induced ROS formation and platelet activation via αIIbβ3, which was quantified
using an antibody to PAC-1 (the first procaspase activating compound), are significantly reduced in
CyPA-deficient mice (CyPA−/−) [60].
Collagen is probably one of the most potent agonists that stimulate ROS-mediated platelet
activation [62]. GPVI, a platelet-specific collagen receptor, has been identified as a receptor that
regulates platelet redox [63]. Arthur et al. showed by immunoprecipitation that the ligation of the
GPVI/FcRγ needs the TNF adapter receptor 4 (TRAF4) to act downstream to enhance ROS production
by NADPH oxidase (NOX) [64]. Indeed, the bridging interaction of TRAF4 with the intracellular GPVI
peptide and the p47phox subunit of NOX allows transduction of the stimuli, which culminates in the
formation of the thrombus. TRAF4 also interacts with other proteins, such as Hic-5, which is linked to
the Src family tyrosine kinase Lyn, in collagen-mediated signal propagation [65]. Moreover, the same
group identified two distinct phases of ROS production. ROS were measured at an early stage in the
presence of a spleen tyrosine kinase (Syk) inhibitor, BAY61-3606. However, 15 to 20 min later, the second
wave of ROS was not observed in the presence of the inhibitor. They concluded that collagen-mediated
platelet activation involves two pathways, a Syk-independent pathway and a Syk-dependent pathway.
This suggests a potential role for ROS in phosphorylation events (see Section 5).
At a later stage, during thrombus formation, oxidative stress leads to enhanced phospholipase
A2 enzyme activity, resulting in the release of arachidonic acid into the cytoplasm [66]. Activated
platelets trigger the conversion of arachidonic acid into a potent platelet aggregation mediator,
thromboxane A2 (TXA2). TXA2 has a pivotal role in that it stabilizes the thrombus and promotes
thrombus growth by recruiting additional platelets. During the conversion of arachidonic acid into
TXA2, cyclooxigenase 1 (COX1) catalyzes the formation of the intermediate prostaglandin H2 and
generates ROS as a by-product [67]. Interestingly, other agonists, such as ADP, soluble CD40 ligand,
and other chemokines, do not detectably increase ROS [31]. This also indicates that ROS production
occurs at a specific time and via a specific pathway during platelet activation.
3.2. NADPH Oxidase
The role of ROS as messengers or mediators of cell signaling is currently widely accepted [68].
Several platelet-related pathways that produce and release ROS have been identified, including
the NOX, COX1, and xanthine pathways [69]. Whereas the latter two pathways produce ROS as
a by-product, the primary function of the NOX pathway is to modulate redox-sensitive signaling
by converting molecular oxygen into the oxygen superoxide anion, O2−· (Figure 2). This involves
the inactivation of phosphotyrosine phosphatases, the activation of certain transcription factors, and
the modulation of ion channels [70]. The NOX pathway not only produces ROS, but it can also
be activated by ROS. Indeed, one hallmark of this pathway is that it responds to a large range of
stimuli, including chemical, physical, environmental, and biological factors [71]. The NOX complex is
activated by cytoplasmic p47phox phosphorylation, which causes it to localize to the cell membrane.
Finazzi-Agrò et al. found that the NOX complex is an essential component for efficient activation in
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platelets, and they demonstrated the release of H2O2 upon platelet activation using scopoletin in a
fluorescence assay [72]. NOX-derived ROS participate in the core stress-response signaling pathway
via the MAPK and c-Jun NH2-terminal kinases [71]. Several groups have investigated the role of ROS
production during platelet activation using NOX−/− mouse cells. Recently, Delaney et al. showed
that enzymatic NOX1 and NOX2 complexes are not part of the same platelet activation pathway [73].
Walsh et al. demonstrated the role of NOX1 in optimal p38MAPK signaling and in subsequent TXA2
production in C57BL6/J background mice [74]. Inhibition of NOX1, either by chemicals such as
2-acetylphenothiazine, diphenylene iodonium, or apocynin, or by the specific peptide-antagonist
gp91, decreases calcium mobilization, which is associated with a decrease in platelet αIIbβ3 activation,
aggregation, and thrombus formation under high shear flow conditions [31,74,75]. On the other hand,
NOX2 knock-out potently inhibits ROS generation under collagen peptide stimulation conditions [73].
In addition, performing the laser-induced arterial thrombosis assay in NOX2−/− mice showed an
effect on thrombus formation but not on bleeding time [73]. These data suggest that ROS are crucial for
efficient hemostasis, while platelet adhesion is less ROS-dependent. In the same way, ROS scavengers
are able to reduce the platelet response to stimuli, highlighting the importance of ROS as secondary
messengers [31,76].
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PLCγ/PKC/MAPKp38 signaling cascade, thereby inducing phospholipase A2 (PLA2) activation via 
(arrows) phosphorylation. PLA2 catalyzes the hydrolysis of the phospholipid sn2-acyl bond at the 
membrane, releasing arachidonic acid (AA) into the cytoplasm. AA can either be converted by COX1 
into prostaglandin G2 (PGG2), an intermediate in the synthesis of thromboxane A2 (TxA2), or it can 
be oxidized by peroxides to form F2 isoprostane (F2-IsoP). Both can bind the prostanoid TP receptor 
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Figure 2. The role of NOX (NOX1 and/or 2) in thrombus formation via ROS production.
Increased intracellular ROS production enhances (+) redox internal signaling. ROS potentiate the
PLCγ/PKC/MAPKp38 signaling cascade, thereby inducing phospholipase A2 (PLA2) activation via
(arrows) phosphorylation. PLA2 catalyzes the hydrolysis of the phospholipid sn2-acyl bond at the
membrane, relea ing arachidonic acid (AA) into the cytoplasm. AA can either be converted by COX1
into prostaglandin G2 (PGG2), an intermediate in the synthesis of thromboxane A2 (TxA2), or it
can be oxidized by peroxides to form F2 isoprostane (F2-IsoP). Both can bind the prostanoid TP
receptor during thrombosis/hemostasis. O2−· can be converted into the more membrane permeable
H2O2 by superoxide dismutase (SOD). H2O2 acts as a second messenger in various cellular signaling
pathways, and it also induces Ca2+ mobilization. Ca2+ mobilization precede the glycoprotein GPIIb/IIIa
(or αIIbβ3) affinity modulation to fibrinogen binding. Alternatively, O2−· reacts with NO, leading to
reactive nitrogen species such as ONOO−.
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3.3. Platelet Activation via ROS
Platelet activation is a complex biological process that involves several signaling pathways [77,78].
Early work in this field established that platelet activation occurs via ROS stimulation, but the
underlying regulatory mechanisms and the target molecules were not well known. The O2−· generated
by NOX can be converted by SOD to H2O2, which is more stable and acts as a second messenger, or to
a hydroxyl radical (OH) [28]. O2−· can also stimulate F2-isoprostane and interact with nitric oxide,
which downregulates platelet activation to form ONOO− (Figure 2). To confirm the role of H2O2
in platelet activation, Dayal et al. overexpressed glutathione-peroxidase-1 in mice [79] and found
significantly reduced platelet activation in response to thrombin stimulation due to the scavenging of
H2O2 by this peroxidase.
Apparently intra-platelet ROS generation is related to αIIbβ3 regulation, rather than to granule
secretion or changes in the shape of platelets [31]. The work of Jang et al. has provided insights into
the collagen/platelet aggregation pathway (Figure 3) [80]. After stimulation of GPVI with collagen,
the Src kinase family of proteins initiates a signaling cascade by phosphorylating the Fc-receptor
γ-chain, which recruits the tyrosine kinase Syk. Syk activates the linker of activated T cells, which
induces the formation of a signaling complex with phospholipase Cγ (PLCγ-2). The subsequent
phosphorylation of PLCγ-2 triggers the hydrolysis of the membrane phospholipid PIP2 into soluble
inositol trisphosphate (IP3) and other signaling molecules. Lastly, once it is bound to the IP3 receptor
(InsP3R, a membrane glycoprotein that acts as a calcium channel), IP3 induces calcium ion mobilization
in the cytosol. Jang et al. identified a redox cysteine switch-off in SHP-2 that plays an important role in
regulating the tyrosine kinases that target the Syk and PLCγ-2 complex [80]. They indirectly measured
cysteine sulfenylation (i.e., R-SOH) by ligation with thiol-reactive biotin to confirm the inhibitory effect
of H2O2 on SHP-2. Furthermore, Krötz et al. showed that the addition of SOD to collagen-stimulated
platelets reduced the release of ADP into the supernatant, thus decreasing platelet recruitment [32].
This could indicate that O2−· participates in platelet recruitment, while H2O2 (formed by the reduction
of O2−· by SOD) is not involved. Taken together, these studies strongly suggest that ROS partially
regulate the activation of integrin αIIbβ3 and the subsequent aggregation of platelets and thrombus
growth (Figure 1).
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Figure 3. Ca2+ mobilization upon stimulation with collagen agonists. Collagen induces the assembly 
of NOX complexes at the membrane. O2−· is converted by SOD into the thiol effector and membrane 
permeable (black arrow) H2O2, which reversibly switches off the SHP-2 phosphatase SHP-2 cysteine 
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Figure 3. Ca2+ mobilization upon stimulation with collagen agonists. Collagen induces the assembly
of NOX complexes at the membrane. O2−· is converted by SOD into the thiol effector and membrane
permeable (black arrow) H2O2, which reversibly switches off the SHP-2 phosphatase SHP-2 cysteine
oxidation inhibits its phosphatase function (black T bars) and results in enhanced (red arrows) kinases
Syk, Vav1, and Btk phosphorylation, essential for the activation of membrane complexes such as
PLCγ-2 and LAT and inducing IP3 release in the cytosol. IP3 acts on the calcium channel, mobilizing
Ca2+ (yellow arrow). Adapted from reference [31], courtesy of Tong-Shin Chang.
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ROS second messengers also negatively regulate platelet function by inducing the shedding of the
platelet GPIbα ectodomain and thus reducing vWF binding [81]. When platelets that were previously
incubated with antioxidants such as N-acetyl cysteine or DTT are stimulated with collagen, thrombin
or A23187, shedding of the ectodomain is partially inhibited. ADAM17/TACE enzyme activation,
which occurs via a p38MAPK-dependent mechanism that is related to intraplatelet oxidative stress,
enables the release of the GPIbα ectodomain [82]. Strong stimulation of platelets and ROS enhance
the formation of the mitochondrial permeability transition (mPT) pore, allowing cytoplasmic calcium
to enter mitochondria. In turn, this stimulates agonist-initiated phosphatidylserine exposure at the
membrane [83]. It appears that thiol groups that are able to cross-link play a critical role in mPT pore
formation, explaining the involvement of ROS. Indeed, McStay et al. showed that under conditions of
oxidative stress, adenine nucleotide translocase can form an intramolecular cross-link between C160
and C257, blocking ATP/ADP exchange at the mitochondrial membrane and enhancing the formation
of the mPT pore [84]. In the context of transfusion medicine, PCs subjected to Mirasol® treatment
showed increased ROS production during storage and specifically on days 2 and 5 of storage [20].
These findings may explain the activation state of inactivated platelets: the redox signaling pathways
could be overstimulated due to the positive ROS imbalance [51] relative to the resting state.
4. Role of Redox Cysteine in Platelets
Free thiol groups and thiol–disulfide exchanges play central roles in the responses of platelets to
stimuli [85]. For example, the reduction of a functional disulfide bond in the β3 extracellular subunit of
the αIIbβ3 receptor, which possesses a redox switch, via inside-out signaling induces conformational
changes that enhance platelet activation [86]. PI-treated PCs, in particular UVB-treated platelets,
have an increased affinity to the PAC-1 antibody, suggesting that the αIIbβ3 receptor undergoes a
conformational change into its active form [8]. In the same way, excessive exposure to UVC illumination
disrupts the disulfide bond in αIIbβ3, thereby enhancing the affinity of the Arg–Gly–Asp (or RGD)
motif for fibrinogen [87]. These studies suggest that UV light has a non-negligible impact on the redox
system in platelets.
Free cysteine residues are the preferred targets for oxidation reactions, and they could be involved
in sensing cellular oxidative stress, as part of a defense mechanism or in cellular regulation. Since
the thiolate (R–S−) attacks the H2O2, the redox potential of protein-free thiols is influenced mainly
by the chemical environment and can modulate R–SH pKa. The reactivity of protein-free thiols could
depend on their accessibility and steric hindrance, since thiol oxidations are substitution nucleophile
bi-molecular (SN2) reactions, implying a concerted backbone in the intermediate [88]. Accordingly,
bulky groups surrounding an R–SH group will decrease its reactivity. Importantly, thiols are good
oxygen acceptors and, among other oxidation states not listed here, can be reversibly transformed into
R–S–S–R, R–SOH or R–SO2H or irreversibly transformed into RSO3H (Table 1). Here we only discuss
reversible cysteine oxidation. Indeed, reversible cysteine oxidation is at the core of the second H2O2
messenger system and, to the best of our knowledge, has not been exhaustively studied in platelets.
Posttranslational cysteine oxidation is reviewed elsewhere [89].
Table 1. Redox cysteine oxidation states.
Name Formulae Oxidation State
Cysteine R–SH −II
Disulfide bridge R–S–S–R −I
Glutathionylation R–S–S–G −I
Sulfenic acid R–SOH 0
Sulfinic acid R–SO2H +II
Sulfonic acid R–SO3H +IV
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4.1. The Involvement of Cysteine in ROS Sensing and Defense
Oxidative stress plays an active role in programmed cell death. Farah and Amberg hypothesized
that the oxidation of cysteine residues in actin is a conserved cellular mechanism that senses oxidative
stress and accelerates cell death [90]. This hypothesis was based on their study in yeast, where the
oxidation of the highly conserved actin Cys-285 and Cys-374 residues impacts actin filaments (F-actin)
polymerization and increases the ROS level. Fixation of the polymerization state of cytoskeletal actin
is part of the apoptosis pathway. Actin assembly and disassembly are not only important in apoptosis;
they are also related to changes in the shapes and the rapid spread of platelets during adhesion
hemostasis (see Section 4.2).
The in vitro hypotonic shock response assay, which tests the capacity of platelets to recover their
initial shape after hypotonic stimulation, showed different results for control platelets versus PI-treated
platelets [24,91,92]. It would be interesting to verify the correlation between ROS imbalance and
poorer cell shape recovery. Notably, PCs have a consistent plasma fraction that contains albumin, the
most abundant plasma protein. Albumin is an important regulator of blood osmotic pressure, and it
transports several substances, like hormones, in the blood. Albumin has also been proposed to act as
an antioxidant, thanks to its high concentration and its ability to capture ROS with its free cysteine
(Cys34). Carbalal et al. proposed sulfenylation of human serum albumin as a mechanism that could
protect plasma free thiols via a mechanism in which ROS are stabilized by Cys34 before the formation
of a disulfide bond [93]. This point of view considers R–SOH to be an intermediate in the formation of
the R–S–S–G moiety, protecting cysteine from further oxidation [89]. As a consequence, albumin could
counter increases in ROS in PCs, thereby playing a protective role against platelet lesions.
In the cytosol, the DJ-1 protein (Parkinson disease protein 7 or PARK7) is suspected to be an
oxidative stress sensor because of its highly conserved Cys106 residue, and it may help protect the
mitochondrial membrane [43]. In our laboratory, we used 2D-GE to show a pI shift of the DJ-1 spot
after INTERCEPT™ treatment, suggesting the presence of an oxidized form of the protein [43]. After
this treatment, more than 20% of the DJ-1 protein was in its oxidized form in PCs [43].
Peroxiredoxin-2 (PrxII) has a similar protective effect against undesired platelet activation and
thrombosis. Recently, the antioxidant behavior of PrxII was correlated with platelet activation by Jang’s
research group, who published a study on SHP-2 [94]. Indeed, PrxII downregulates GPVI-mediated
platelet activation by efficiently trapping H2O2, thereby preventing SHP-2 sulfenylation and
subsequent inactivation. PrxII antithrombotic activity was also validated in vivo using an arterial
injury assay to investigate mice lacking the PRDXII gene [94].
4.2. Cysteine-Mediated Redox Signaling
Cells can exploit reversible thiol oxidation to transduce stimuli, for example via disulfide bonds
and sulfenic acids. The difficulties in detecting the sulfenic acid moiety, –SOH, is due mainly to
its much lower pKa: it easily undergoes RSO−, which is a better nucleophile then thiolate R–S−,
and this enhances its reactivity with other molecules [95]. This reversible and therefore transitory
oxidation-based post-translational modification (oxPTM) is probably, like phosphorylation-based
PTMs, part of a binary switch that modulates protein activity [96]. Oxidative disulfide formation
is enhanced by H2O2 and can be involved in the formation of protein complexes or conformational
changes that modulate protein function. Phosphotyrosine phosphatases are among the best understood
examples of oxidative disulfide formation. In this case, a free cysteine thiol is reversibly converted
to a sulfenic acid, inactivating the phosphatase function. It has been proposed that such oxPTMs are
part of a widespread and highly conserved redox regulation mechanism that works in conjunction
with receptor tyrosine kinases [97]. Inhibition of phosphotyrosine phosphatases enhances tyrosine
phosphorylation (e.g., SHP2; see Section 3.3). There are other sulfenic acid-mediated mechanisms as
well. In addition to oxidative folding, which occurs mainly in the endoplasmic reticulum, disulfide
bond formation that is driven by R–SOH intermediates is involved in the assembly of protein complexes.
One example is protein kinase A, in which disulfide bond formation between regulatory subunits is
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driven by an R–SOH intermediate and acts to induce the translocation of a protein complex from the
cytosol to the cytoplasmic membrane [98].
Disulfide bonds should not only be considered entities that stabilize protein tertiary structure or
that act as a defense mechanism. Indeed, Fiaschi et al. showed the importance of the formation of a
mixed disulfide bond (i.e., the glutathionylation of actin Cys374) in enhancing the dynamic spread of
murine fibroblasts and their adhesion via cytoskeletal rearrangement [99]. Their conclusion was based
on the observation that glutathione depletion or the Cys–374–Ala substitution importantly affected
actin fiber formation and fibroblast adhesion, further confirming their model based on the involvement
of ROS production on integrin-mediated adhesion to extracellular matrix [100,101]. Thiol-disulfide
exchanges also represent a redox switch in protein function [102]. The thiol oxidoreductase protein
disulfide isomerase (PDI) is particularly interesting in the context of this review because it is secreted
(inside T-granules) by platelets during activation [103]. Platelet PDI targets the extracellular domain of
αIIbβ3 and therefore mediates thrombus formation. Indeed, intravital microscopy demonstrated that
the accumulation of PDI at the site of laser-induced arteriolar wall injury was markedly decreased in
β3−/− mice [104]. Another mechanism by which PDI participates in thrombus formation involves the
upregulation of NOX1 and NOX2, which increases ROS production [105].
Several PC proteins that are affected by PITs are mitochondrial proteins or proteins that are
involved in preserving mitochondrial integrity [37]. The mitochondrial environment is the richest
environment in the cell in terms of free cysteine thiols, and this contributes to mitochondrial
characteristics and function [88]. Given the alkaline environment of the inner mitochondria due to
protons being pumped into the intermembrane space, free cysteines are likely to be in the thiolate form.
ROS are produced continuously along the oxidative phosphorylation chain. As a consequence, free
thiols can easily be oxidized to R–SOH or even to higher oxidation states (Table 1). In the mitochondrial
matrix, as in other cell compartments, glutathione reacts with thiolates to protect protein function
when there is an H2O2 imbalance.
5. ROS-Phosphorylation Crosstalk
Protein phosphorylation is one of the most important regulatory mechanisms in cell biology [106].
Among the reversible PTMs, phosphorylation is one of the most studied and best understood. The types
and levels of kinases and phosphatases inside cells highlight the importance of phosphorylation as
a regulatory mechanism. Furthermore, kinases and phosphatases are often in competition with
respect to their target proteins, and many proteins and enzymes are regulated by phosphorylation
at multiple sites. Protein phosphorylation is easily detected by Western blot analysis and by 2D-GE
techniques [107]. Current mass spectrometry-based proteomic techniques permit the study of the
phosphorylation level after phospho-peptide enrichment, allowing researchers to conduct untargeted
experiments and thereby gain an overview of phosphorylation in cells [108,109]. In signal transduction,
phosphorylation is often induced by first messengers, such as hormones and paracrine/autocrine
agents, and it can act in a concerted way with second messengers like calcium ions, redox signaling
molecules, nitric oxide and lipophilic molecules.
Interestingly, the link between UVB-ROS-phosphorylation and platelet activation was suggested
by Van Marwijk Kooy et al. in 1993 [110]. They observed that after UVB illumination of platelets,
there was increased fibrinogen binding that correlated with a 40% higher level of phosphorylation
downstream of protein kinase C. UV-induced phosphorylation and platelet aggregation were
significantly reduced in the presence of SOD and catalase, respectively, which are scavengers of
O2−· and H2O2. They concluded that the ROS generated upon UVB exposure induces platelet
activation-aggregation via protein kinase C. Later, Schubert’s group provided an important example
of the impact of UVB-based PIT on the PTM proteome [111]. They used 1D gel semi-quantitative
proteomics and phospho-immunoblotting and found that apheresis platelet bags resulted in
enhanced phosphorylation of the vasodilator-stimulated phosphoprotein (VASP) after riboflavin-UVB
treatment [111]. VASP is a highly concentrated cytosolic platelet protein involved in the ADP
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activation cascade, which promotes F-actin elongation. Its phosphorylation on Ser-157 and Ser-239
strongly correlates with αIIbβ3 binding to soluble fibrinogen and with platelet aggregation [112].
This observation led to the development of an in vitro assay that is currently in clinical use that tests
the efficacy of antiplatelet treatments (such as clopidogrel, which binds to the P2Y12 receptor) on
VASP phosphorylation [113]. This group investigated upstream kinase activity and showed that
inhibiting p38MAPK after PIT treatment (Mirasol® in their study) significantly restored PC quality
based on in vitro tests [114]. Indeed, the phosphorylation level was tested in treated versus untreated
PCs, and the results showed that kinases had enhanced activity after exposure to UVB. In particular,
p38MAPK showed a greater than two-fold increase in activity [114]. Finally, they demonstrated that the
enhanced p38MAPK kinase activity induced by Mirasol® treatment triggered apoptosis in apheresis
PCs [115]. Moreover, they also showed that Mirasol® treatment potentiates the phosphorylation of
NF-κB and IκBα, enhancing redox-sensitive transcription activity [20]. In the context of this review,
these findings suggest that the ROS produced during pathogen inactivation can interfere with protein
phosphorylation and impact internal cell signaling.
The possible links between oxidative stress and cell signaling raise some fascinating possibilities.
Recently, in human epidermoid carcinoma cells, Carroll’s group demonstrated that endothelial growth
factor receptor (EGFR) kinase activity is modulated by the oxidation of Cys979 into sulfenic acid after
H2O2 reacts with its free thiol [116]. They optimized an experimental strategy for the site-specific
analysis of protein –SOH that uses a sulfenic acid-specific probe (DYn-2) to fix this labile redox cysteine
state. This allows sulfenylation to be studied in cells over time, and they specifically compared the basal
sulfenylome with one in stressed conditions following H2O2 stimulation of RKO and A431 cells [117].
The identification of the sulfenic acid sites allowed the mechanistic study of activation-translocation of
the transcription factor HIF1A by SIRT6. Our laboratory is currently using this strategy to characterize
the platelet sulfenylome (Sonego, G.; Prudent, M.; et al., Mapping the platelet sulfenylome, Manuscript
in writing process). Our aim is to assess the impact of PITs on PCs and to elucidate the connection
between ROS second messengers that are produced during PC treatment and PC functionality in vitro.
6. The Overlap of Redox Proteomics and Transfusion
The storage conditions for PCs are continuously being changed and improved, with the result
that different countries use different storage conditions. These changes also raise the issue of the
cost-effectiveness of incremental improvements. Changes in storage conditions have suggested
interesting new possibilities, and clinical trials must be continuously updated to reflect the changes.
Moreover, improved clinical monitoring methods and the use of advanced analytical tests are being
used to reassess abandoned practices for use in specific applications [118]. For example, whole blood
storage, platelet cryopreservation and cold storage have been reconsidered for hemorrhagic shock
treatment [119–121]. Cold storage at 4 ◦C has shown positive outcomes, and platelet function is
conserved until day 15 in these conditions [119]. Therefore the field is evolving, and there is a danger
that debate about the convenience of RT platelet storage could destabilize the paradigm. Along with
other authors, Cap has criticized the RT storage, asserting that post-transfusion platelet recovery is not
a universal criterion for platelet function and does not guarantee efficacy in the context of the targeted
condition beyond prophylactic treatment [122]. While the debate over optimal PC storage conditions
is not the focus of the present review, in terms of the advantages and disadvantages, costs, product
availability, effectiveness, etc., we would like to make the point that “omic” research approaches can
help clinicians and blood bankers make better medical decisions.
6.1. The Impact of Antioxidants on PI-Treated PCs
PITs are photochemical treatments or photo-treatments that induce oxidative lesions. Our lab has
demonstrated the effects of PITs on oxidative processes in platelets by showing an important decrease
in extracellular antioxidant power after INTERCEPT® treatment; the same effects were seen with our
laboratory’s in-house riboflavin/UVB system [24]. Antioxidant power was measured electrochemically
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using EDEL technology (in arbitrary units equivalent to one micromolar ascorbic acid) by deposing
a 2 µL drop of liquid sample on a microchip. [123,124]. Using the results, our group developed
a quality control assay to assess the effects of PIT before product delivery [123]. One solution for
countering the oxidative damage of PITs that has been proposed in the literature is to supplement
PCs with antioxidants. A few studies have tested the ability of added antioxidants to decrease the
carbonylation level during platelet storage/aging and to reduce oxidative stress [125,126]. The idea
is that antioxidants will directly scavenge ROS and protect cellular components like glutathione.
However, this supplementation is questionable and would have to be fine-tuned as antioxidants clearly
modulate platelet function.
Olas and Wachowitz studied the effect of resveratrol and vitamin C on the inhibition of ROS
production [127]. Vitamin C concentrations of 0.75 to 3 mM showed good effectiveness against ROS,
while resveratrol only partially inhibited ROS production. Sobotkova et al. showed the antioxidant
properties of resveratrol on washed platelets using trolox, a hydrophilic analog of vitamin E, using
an equivalent antioxidant capacity assay and indirect measurements of OH· following salicylic acid
hydroxylation into 2,3-DHB and 2,5-DHB [128]. Importantly, resveratrol, which is naturally found in
wine, seems to modulate key proteins involved in intracellular signaling, including effects on protein
kinase activation (p38MAPK), phospholipase C, the Ca2+ cascade and the activation of NO/cyclic
GMP [129]. However, due to suggested differences in redox-sensitive pathways, the inhibition of
platelet activation by antioxidants remains limited by their specific properties [57]. ROS production
that is induced by PIT may be randomly distributed inside the cell or it may be concentrated in the
vicinity of DNA and RNA molecules, especially in the case of amotosalen, which is an intercalation
compound with chemical activity that differs from riboflavin. In addition, there is a risk that the use of
antioxidants during the PI process will decrease the PI efficacy by quenching the effect of the treatment.
Lastly, antioxidants such as vitamin E and β-carotene inhibit the primary function of platelets and
are suspected of being associated with hemorrhagic stroke in male patients with lung cancer [130].
Antioxidants that protect supernatant proteins and the integrity of platelet membranes probably have
the best chance of success.
6.2. Cold Storage and Cryopreservation
There are several possible strategies for reducing or eliminating the risk of bacterial growth
during RT storage while avoiding the use of PITs and without shortening storage time. Cold storage
and cryopreservation are among the possible solutions. Cold storage has not been in general use
since the 1970s. Despite shortened recirculation issues, recent clinical studies have shown that
cold-stored products have potential for use for specific treatments [131]. Cryopreserved platelets
have an obvious advantage in terms of overcoming the issue of short shelf life. Recently, autologous
cryopreserved platelets were successfully transfused into HLA-alloimmunized patients, showing
good conservation of their function in the presence of strong agonists [132]. However, relative to
storage at RT, low temperature storage (both at 4 and −80 ◦C) results in platelet hyperactivity.
In cryopreserved platelets, it has been hypothesized that the development of a pro-coagulant phenotype
at the membrane underlies the altered in vivo hemostatic activity [133]. Moreover, the activation of
cryopreserved platelets seems to occur via exposure of P-selectin at the platelet and microparticle
membranes [120]. Measurement of dynamic light scattering (DLS) scores using the ThromboLUXTM
system showed significant differences in particle composition between RT-stored platelets and
cold-stored or cryopreserved platelets, suggesting increased microparticulation in response to storage
at low temperature [121].
Redox regulation of platelet microparticulation is still poorly understood, but elevated levels
of microparticles are associated with inflammatory diseases, such as arterial thrombosis, diabetes,
rheumatoid arthritis and ischemic events [134,135]. Holbrook et al. showed that thrombin stimulation
of platelets induces the shedding of microparticles containing PDI and ERp57, both of which are
disulfide isomerases [136]. We mentioned above that the PDI on the platelet surface can regulate the
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cysteine-rich β3 region of the αIIbβ3 integrin as well as the affinity of αIIbβ3 for fibrinogen. Essex and
Li significantly downregulated the affinity of αIIbβ3 for PAC-1, specifically by inhibiting PDI activity
with rabbit anti-PDI IgG [137]. Therefore, cold stored and cryopreserved platelets most likely show
hyperactivation relative to RT-stored platelets due to increased microparticulation [120]. Nevertheless,
PDI is not the only disulfide isomerase to act at the platelet surface. Holbrook and coworkers identified
several new disulfide isomerases on the platelet surface using immunoblotting [136]. Confirming
intense oxidoreductase activity at the platelet membrane, PDI was found to be released by platelets
during injury as an activator of the tissue factor that initiates fibrin polymerization after thrombin
activation [138]. Indeed, PDI catalyzes the formation of an intra-disulfide bond between a mixed
disulfide (i.e., GSSR) and a free thiol on the tissue factor. Moreover, low temperature storage
seems to affect redox regulation by enhancing the capacity of platelets to synthetize TxA2 via AA
stimulation [139]. In spite of these differences relative to PI-treated platelets, a number of clinical
studies have been conducted using platelets that were stored at low temperatures, and they were
shown to be safe and thus to represent a real option for patients.
6.3. Whole Blood Inactivation and Cold Storage
Pathogen inactivation to prevent transfusion-transmitted infections has become a central
paradigm in transfusion medicine. While several countries have adopted regulations for PIT use
in PC manufacturing, others still need to upgrade their blood supply systems. PITs have been used
during infection crises, for example in the Chikungunya outbreak on Reunion Island, to avoid the
collapse of the blood component supply [140]. Therefore, PITs are currently part of the arsenal used to
fight emerging pathogens. Unfortunately, UVA-based PITs cannot be used to inactivate red blood cell
(RBC) concentrates or even whole blood. Due to the overlapping absorption spectra of hemoglobin
and its high concentration in blood, technologies that employ UVA radiation damage RBCs, increasing
the risk of an immune response in the recipient [141]. To overcome this barrier to use, a chemical-based
S-303 inactivating system has been developed that uses glutathione combined with the amphipathic
chemical compound S-303 [142]. The membrane-permeable compound comprises a linker that can
covalently bind to RNA/DNA, blocking their replication, plus an inert tail reporter released upon the
binding of nucleotides. Glutathione molecules, which are not membrane permeable, quench the S-303
side reactions, protecting proteins and other extracellular components. This system avoids the use
of photochemistry to inactivate pathogens. The first evidence that S-303 can be used to treat whole
blood was presented by Mufti et al. [143]. Treatment of whole blood could simplify the pathogen
inactivation process, allowing the treated blood to subsequently be used to obtain plasma, platelets and
RBC components via the buffy coat method. However, S-303-based inactivation does have an impact
on cells. Indeed, erythrocyte concentrates showed decreased glycolysis and increased extracellular
potassium levels after treatment with S-303 [143]. Due to its affordability and potential for widespread
use, the idea of treating whole blood has also been tested using the Mirasol® system. To assess the
suitability of the UVB/riboflavin treatment for whole blood, the viability of the different components
was tested in vitro. Schubert et al. found significant deterioration in plasma coagulation factor
activation and increased RBC aging in components derived from whole blood that was PI-treated [144].
Interestingly, platelets showed fewer lesions than PI-treated PCs. Again, further studies are needed to
clarify the effects of this system on specific molecular components.
As a final remark, it is important to notice that all developments and innovations in transfusion
medicine must be based not only on scientific data but also on safety and economic issues.
7. Conclusions
In platelets, the ROS balance controls both platelet activation and the platelet aggregation process.
In the context of transfusion medicine, PITs slightly disturb the resting state of platelets. The clinical
impact of this disturbance is not completely understood, although the safety of PITs has been shown.
However, in vitro tests show evidence of lesions in treated PCs. Considering the increase in the protein
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carbonylation level in PI-treated PCs, it is reasonable to suspect that these lesions activate platelets
via ROS. ROS are very reactive small molecules that can transduce stimuli into biological responses.
Although the link between second messenger ROS and platelet activation is now well known, the
molecular mechanisms that regulate this process remain to be elucidated. As described here, the
redox potential of cysteine plays a central role in signal transduction. Accordingly, PITs that produce
oxidative stress could drive the creation of PCs that contain platelets that are slightly hyperactive,
show increased lesions with increased storage time, and may not be well suited to the characteristics of
the recipient. Alternative storage conditions could be suited to other clinical status; we must more fully
understand the in vitro functionality of platelets to fully understand the clinical implications of PITs.
Advanced proteomics, and in particular redox proteomics, are of primary importance for
deciphering the defined steps in the platelet activation and aggregation processes. As highlighted here,
the identification of platelet sulfenylation sites, among other oxPTM sites, will help researchers select
candidate proteins that are sensitive to ROS and help to better characterize the final labile blood product.
The discovery of these oxidative mechanisms could go beyond concerns about transfusion and give us
a better understanding of inflammatory diseases that are accompanied by platelet hyperactivity [127].
Finally, from the viewpoint of blood centers, further basic and “omic” research that investigates
redox regulations, as reviewed here, will be helpful for developing innovative and improved strategies
for preparing and storing platelets. Although this work is promising, the relationships between platelet
biochemistry and clinical effects must be elucidated further, and redox proteomics studies of PCs
should ideally be accompanied by functional tests. Moreover, it is important to question the value and
potential of current PITs and to think about the possibility of novel inactivation systems that do not
rely on oxidative stress, such as whole blood inactivation, which does not use UV light.
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Abbreviations
2D-GE Two dimensional-gel electrophoresis
F-actin Actin filaments
AA Ascorbic acid
CCI Corrected count increment
COX1 Cyclooxygenase 1
CyPA Cyclophilin A
DCF 2′,7′-dichlorofluorescein
F2-IsoP F2 isoprostane
GP-Ib-IX Glycoprotein Ib-IX
GPVI Glycoprotein VI
H2DCFDA 2′,7′-dichlorodihydrofluorescein diacetate
IP3 Isoprostane 3
LAT Linker of activated T-cells
mPT Mitochondria permeability transition
NOX NADPH oxidase
PC Platelet concentrate
PDI Protein disulfide isomerase
PGG2 Prostaglandin G2
PI Pathogen inactivation
PIT Pathogen inactivation technology
PLA2 Phospholipase A2
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PLCg-2 Phospholipase Cg 2
PrxII Peroxiredoxin-II
PTM Post-translational modification
oxPTM Oxidative PTM
RBC Red blood cell
ROS Reactive oxygen species
RT Room temperature
SOD Superoxide dismutase
TRAF4 TNF receptor associated factor 4
TXA2 Thromboxane A2
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